{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:52:51Z","timestamp":1791273171851,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.iac.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:55:35Z","timestamp":1785455735000},"page":"639-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practical Guidance for Systemic Treatment Selection in Pediatric Refractory Atopic Dermatitis"],"prefix":"10.1016","volume":"46","author":[{"given":"Suchita","family":"Sampath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Mosser-Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.iac.2026.06.006_bib1","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.det.2024.05.004","article-title":"Global burden of atopic dermatitis: examining disease prevalence across pediatric and adult populations world-wide","volume":"42","author":"Puerta Durango","year":"2024","journal-title":"Dermatol Clin"},{"issue":"4","key":"10.1016\/j.iac.2026.06.006_bib2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jaad.2016.05.028","article-title":"Persistence of atopic dermatitis (AD): a systematic review and meta-analysis","volume":"75","author":"Kim","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.iac.2026.06.006_bib3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamadermatol.2018.1572","article-title":"Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis","volume":"154","author":"Simpson","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.iac.2026.06.006_bib4","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/pde.15327","article-title":"Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines","volume":"40","author":"Siegfried","year":"2023","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.006_bib5","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2292962","article-title":"The wide variety of methotrexate dosing regimens for the treatment of atopic dermatitis: a systematic review","volume":"35","author":"Caron","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"6","key":"10.1016\/j.iac.2026.06.006_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/bjd\/ljad281","article-title":"Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial","volume":"189","author":"Flohr","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.006_bib7","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"9513","key":"10.1016\/j.iac.2026.06.006_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.iac.2026.06.006_bib9","first-page":"387","article-title":"New and emerging trends in the treatment of atopic dermatitis","volume":"2","author":"Gelbard","year":"2008","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"10.1016\/j.iac.2026.06.006_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.iac.2026.06.006_bib11","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.3390\/jcm14144960","article-title":"Comparative efficacy and safety of tralokinumab and dupilumab in moderate-to-severe atopic dermatitis: a narrative review","volume":"14","author":"Kim","year":"2025","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.iac.2026.06.006_bib12","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","article-title":"Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-Week, open-label, phase 3 study","volume":"13","author":"Paller","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.iac.2026.06.006_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s13555-025-01357-7","article-title":"Lebrikizumab vs other systemic monotherapies for moderate-to-severe atopic dermatitis: network meta-analysis of efficacy","volume":"15","author":"Silverberg","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.iac.2026.06.006_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0319400","article-title":"Comparative efficacy and safety of dupilumab versus newly approved biologics and JAKi in pediatric atopic dermatitis: a systematic review and network meta-analysis","volume":"20","author":"Liao","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.iac.2026.06.006_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6\u201312 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2024","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.iac.2026.06.006_bib16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s13555-024-01243-8","article-title":"Practical recommendations on laboratory monitoring in patients with atopic dermatitis on oral JAK inhibitors","volume":"14","author":"Kirchhof","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10246","key":"10.1016\/j.iac.2026.06.006_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.iac.2026.06.006_bib18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/jamadermatol.2023.0391","article-title":"Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the measure up 1, measure up 2, and AD up randomized clinical trials","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.iac.2026.06.006_bib19","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: living systematic review and network meta-analysis update","volume":"160","author":"Drucker","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2026.06.006_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaad.2020.11.002","article-title":"Pediatric allergic contact dermatitis. Part I: clinical features and common contact allergens in children","volume":"84","author":"Neale","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.006_bib21","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1089\/derm.2024.0005","article-title":"Characterization of pediatric patch testing: a retrospective review, 2020-2023","volume":"35","author":"Brumley","year":"2024","journal-title":"Dermatitis"},{"issue":"4","key":"10.1016\/j.iac.2026.06.006_bib22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/derm.2023.0353","article-title":"Pediatric patch testing at Mayo clinic between 2016 and 2020","volume":"35","author":"Wang","year":"2024","journal-title":"Dermatitis"},{"issue":"9","key":"10.1016\/j.iac.2026.06.006_bib23","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3390\/diagnostics12092177","article-title":"Atopic dermatitis-like genodermatosis: disease diagnosis and management","volume":"12","author":"Pan","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.iac.2026.06.006_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15901","article-title":"Children atopic dermatitis: diagnosis, mimics, overlaps, and therapeutic implication","volume":"35","author":"Napolitano","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.iac.2026.06.006_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242642","article-title":"Generalised eczema: a diagnostic clue to Wiskott-Aldrich syndrome","volume":"14","author":"Kumar","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.iac.2026.06.006_bib26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/s41390-025-03941-1","article-title":"Dupilumab successfully controlled eczema in Wiskott-Aldrich syndrome over 52 weeks","volume":"98","author":"Zhu","year":"2025","journal-title":"Pediatr Res"},{"issue":"11","key":"10.1016\/j.iac.2026.06.006_bib27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jamadermatol.2022.3796","article-title":"Netherton syndrome","volume":"158","author":"Drivenes","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2026.06.006_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.645259","article-title":"Netherton syndrome in children: management and future perspectives","volume":"9","author":"Barbati","year":"2021","journal-title":"Front Pediatr"},{"issue":"3","key":"10.1016\/j.iac.2026.06.006_bib29","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/jamadermatol.2019.4608","article-title":"Treatment of Netherton syndrome with dupilumab","volume":"156","author":"Steuer","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2026.06.006_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2006.08.015","article-title":"Acrodermatitis enteropathica and an overview of zinc metabolism","volume":"56","author":"Maverakis","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.006_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0738-081X(00)00150-4","article-title":"Acrodermatitis enteropathica","volume":"18","author":"Sehgal","year":"2000","journal-title":"Clin Dermatol"},{"issue":"12","key":"10.1016\/j.iac.2026.06.006_bib32","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/ijd.16098","article-title":"Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management","volume":"61","author":"Kothari","year":"2022","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.iac.2026.06.006_bib33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","article-title":"Langerhans cell histiocytosis in children: history, classification, pathobiology, clinical manifestations, and prognosis","volume":"78","author":"Krooks","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856126000615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:25:16Z","timestamp":1791271516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856126000615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0889856126000615"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.006","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Practical Guidance for Systemic Treatment Selection in Pediatric Refractory Atopic Dermatitis","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}